Clusters of microcalcification, known as psammoma bodies, are frequently observed in papillary carcinomas.

Thyroid cancer rarely causes hyperthyroidism or hypothyroidism as it does not usually secrete thyroid hormones. The most common type of thyroid cancer is papillary carcinoma, which is often found in young females and has an excellent prognosis. Follicular carcinoma is less common, while medullary carcinoma is a cancer of the parafollicular cells that secrete calcitonin and is associated with multiple endocrine neoplasia type 2. Anaplastic carcinoma is rare and not responsive to treatment, causing pressure symptoms. Lymphoma is also rare and associated with Hashimoto’s thyroiditis.

Management of papillary and follicular cancer involves a total thyroidectomy followed by radioiodine to kill residual cells. Yearly thyroglobulin levels are monitored to detect early recurrent disease. Papillary carcinoma usually contains a mixture of papillary and colloidal filled follicles, while follicular adenoma presents as a solitary thyroid nodule and malignancy can only be excluded on formal histological assessment. Follicular carcinoma may appear macroscopically encapsulated, but microscopically capsular invasion is seen. Medullary carcinoma is associated with raised serum calcitonin levels and familial genetic disease in up to 20% of cases. Anaplastic carcinoma is most common in elderly females and is treated by resection where possible, with palliation achieved through isthmusectomy and radiotherapy. Chemotherapy is ineffective.

SGLT2 inhibitors are known as gliflozins.

Sulfonylurea refers to tolbutamide.

GLP-1 receptor agonist is exenatide.

DPP-4 inhibitor is linagliptin.

Understanding SGLT-2 Inhibitors

SGLT-2 inhibitors are medications that work by blocking the reabsorption of glucose in the kidneys, leading to increased excretion of glucose in the urine. This mechanism of action helps to lower blood sugar levels in patients with type 2 diabetes mellitus. Examples of SGLT-2 inhibitors include canagliflozin, dapagliflozin, and empagliflozin.

However, it is important to note that SGLT-2 inhibitors can also have adverse effects. Patients taking these medications may be at increased risk for urinary and genital infections due to the increased glucose in the urine. Fournier’s gangrene, a rare but serious bacterial infection of the genital area, has also been reported. Additionally, there is a risk of normoglycemic ketoacidosis, a condition where the body produces high levels of ketones even when blood sugar levels are normal. Finally, patients taking SGLT-2 inhibitors may be at increased risk for lower-limb amputations, so it is important to closely monitor the feet.

Despite these potential risks, SGLT-2 inhibitors can also have benefits. Patients taking these medications often experience weight loss, which can be beneficial for those with type 2 diabetes mellitus. Overall, it is important for patients to discuss the potential risks and benefits of SGLT-2 inhibitors with their healthcare provider before starting treatment.

Diagnosis and Symptoms of Hypothyroidism

Hypothyroidism is diagnosed through blood tests that show low levels of T4 and elevated levels of TSH. Physical examination may reveal slow relaxation of tendon jerks, bradycardia, and goitre. A bruit over a goitre is associated with Graves’ thyrotoxicosis, while palmar erythema and fine tremor occur in thyrotoxicosis. In addition to these common symptoms, hypothyroidism may also present with rarer features such as cerebellar features, compression neuropathies, hypothermia, and macrocytic anaemia. It is important to diagnose and treat hypothyroidism promptly to prevent further complications.

Gynaecomastia can be caused by testicular conditions such as seminoma that secrete hCG.

Understanding Gynaecomastia: Causes and Drug Triggers

Gynaecomastia is a condition characterized by the abnormal growth of breast tissue in males, often caused by an increased ratio of oestrogen to androgen. It is important to distinguish the causes of gynaecomastia from those of galactorrhoea, which is caused by the actions of prolactin on breast tissue.

Physiological changes during puberty can lead to gynaecomastia, but it can also be caused by syndromes with androgen deficiency such as Kallmann and Klinefelter’s, testicular failure due to mumps, liver disease, testicular cancer, and hyperthyroidism. Additionally, haemodialysis and ectopic tumour secretion can also trigger gynaecomastia.

Drug-induced gynaecomastia is also a common cause, with spironolactone being the most frequent trigger. Other drugs that can cause gynaecomastia include cimetidine, digoxin, cannabis, finasteride, GnRH agonists like goserelin and buserelin, oestrogens, and anabolic steroids. However, it is important to note that very rare drug causes of gynaecomastia include tricyclics, isoniazid, calcium channel blockers, heroin, busulfan, and methyldopa.

In summary, understanding the causes and drug triggers of gynaecomastia is crucial in diagnosing and treating this condition.

The development of Hashimoto’s thyroiditis is linked to

Understanding Hashimoto’s Thyroiditis

Hashimoto’s thyroiditis is a chronic autoimmune disorder that affects the thyroid gland. It is more common in women and is typically associated with hypothyroidism, although there may be a temporary period of thyrotoxicosis during the acute phase. The condition is characterized by a firm, non-tender goitre and the presence of anti-thyroid peroxidase (TPO) and anti-thyroglobulin (Tg) antibodies.

Hashimoto’s thyroiditis is often associated with other autoimmune conditions such as coeliac disease, type 1 diabetes mellitus, and vitiligo. Additionally, there is an increased risk of developing MALT lymphoma with this condition. It is important to note that many causes of hypothyroidism may have an initial thyrotoxic phase, as shown in the Venn diagram. Understanding the features and associations of Hashimoto’s thyroiditis can aid in its diagnosis and management.

The age of the baby is an important factor in determining the possible causes of neonatal jaundice. Congenital hypothyroidism may be responsible for prolonged jaundice in newborns. The following is a summary of the potential causes of jaundice based on the age at which it appears:

Jaundice within 24 hours of birth may be caused by haemolytic disease of the newborn, infections, or G6PD deficiency.

Jaundice appearing between 24-72 hours may be due to physiological factors, sepsis, or polycythaemia.

Jaundice appearing after 72 hours may be caused by extrahepatic biliary atresia, sepsis, or other factors.

Understanding Congenital Hypothyroidism

Congenital hypothyroidism is a condition that affects approximately 1 in 4000 newborns. If left undiagnosed and untreated within the first four weeks of life, it can lead to irreversible cognitive impairment. Some of the common features of this condition include prolonged neonatal jaundice, delayed mental and physical milestones, short stature, a puffy face, macroglossia, and hypotonia.

To ensure early detection and treatment, children are screened for congenital hypothyroidism at 5-7 days of age using the heel prick test. This test involves taking a small sample of blood from the baby’s heel and analyzing it for thyroid hormone levels. If the results indicate low levels of thyroid hormone, the baby will be referred for further testing and treatment.

It is important for parents and healthcare providers to be aware of the signs and symptoms of congenital hypothyroidism and to ensure that newborns receive timely screening and treatment to prevent long-term complications. With early detection and appropriate management, children with congenital hypothyroidism can lead healthy and fulfilling lives.

Leptin is the hormone that lowers appetite, while ghrelin is the hormone that increases appetite. Leptin is produced by adipose tissue and plays a crucial role in regulating feelings of fullness and satiety. Mutations that affect leptin signaling can lead to severe childhood-onset obesity. On the other hand, ghrelin is known as the hunger hormone and stimulates appetite. However, decreased ghrelin synthesis does not cause obesity. Insulin is an anabolic hormone that promotes glucose uptake and lipogenesis, while obestatin’s role in satiety is still controversial.

The Physiology of Obesity: Leptin and Ghrelin

Leptin is a hormone produced by adipose tissue that plays a crucial role in regulating body weight. It acts on the hypothalamus, specifically on the satiety centers, to decrease appetite and induce feelings of fullness. In cases of obesity, where there is an excess of adipose tissue, leptin levels are high. Leptin also stimulates the release of melanocyte-stimulating hormone (MSH) and corticotrophin-releasing hormone (CRH), which further contribute to the regulation of appetite. On the other hand, low levels of leptin stimulate the release of neuropeptide Y (NPY), which increases appetite.

Ghrelin, on the other hand, is a hormone that stimulates hunger. It is mainly produced by the P/D1 cells lining the fundus of the stomach and epsilon cells of the pancreas. Ghrelin levels increase before meals, signaling the body to prepare for food intake, and decrease after meals, indicating that the body has received enough nutrients.

In summary, the balance between leptin and ghrelin plays a crucial role in regulating appetite and body weight. In cases of obesity, there is an imbalance in this system, with high levels of leptin and potentially disrupted ghrelin signaling, leading to increased appetite and weight gain.

The hormone ADH (also known as vasopressin) is secreted by the posterior pituitary gland and acts in the collecting ducts of the kidneys to increase water reabsorption. Unlike ADH, all of the other hormone options presented are released from the anterior pituitary. ACTH is a component of the hypothalamic-pituitary-axis and increases the production and release of cortisol from the adrenal gland. GH (also called somatotropin) is an anabolic hormone that stimulates growth in childhood and has metabolic effects on protein, glucose, and lipids. FSH is a gonadotropin that promotes the maturation of germ cells.

Thyroid disorders are commonly encountered in clinical practice, with hypothyroidism and thyrotoxicosis being the most prevalent. Women are ten times more likely to develop these conditions than men. The thyroid gland is a bi-lobed structure located in the anterior neck and is part of a hypothalamus-pituitary-end organ system that regulates the production of thyroxine and triiodothyronine hormones. These hormones help regulate energy sources, protein synthesis, and the body’s sensitivity to other hormones. Hypothyroidism can be primary or secondary, while thyrotoxicosis is mostly primary. Autoimmunity is the leading cause of thyroid problems in the developed world.

Thyroid disorders can present in various ways, with symptoms often being the opposite depending on whether the thyroid gland is under or overactive. For example, hypothyroidism may result in weight gain, while thyrotoxicosis leads to weight loss. Thyroid function tests are the primary investigation for diagnosing thyroid disorders. These tests primarily look at serum TSH and T4 levels, with T3 being measured in specific cases. TSH levels are more sensitive than T4 levels for monitoring patients with existing thyroid problems.

Treatment for thyroid disorders depends on the cause. Patients with hypothyroidism are given levothyroxine to replace the underlying deficiency. Patients with thyrotoxicosis may be treated with propranolol to control symptoms such as tremors, carbimazole to reduce thyroid hormone production, or radioiodine treatment.

The decrease in renal phosphate reabsorption is caused by PTH.

The symptoms presented are indicative of a kidney stone, which can be a sign of hyperparathyroidism. Primary hyperparathyroidism, caused by a functioning parathyroid adenoma, can result in low phosphate and high calcium levels. PTH reduces renal phosphate reabsorption, leading to increased phosphate loss in urine. Pituitary adenomas are associated with osteoporosis due to excessive PTH causing bone resorption.

PTH activates vitamin D, which increases phosphate absorption in the gastrointestinal tract. However, the renal loss of phosphate is greater than the increase in absorption, resulting in a net loss of phosphate when PTH levels are high.

PTH also increases renal vitamin D activation, leading to increased intestinal absorption of calcium and phosphate, as well as increased osteoclast activity. This results in elevated levels of serum calcium and phosphate.

Hypothyroidism does not significantly affect phosphate regulation, so it would not cause low serum phosphate levels.

Increased osteoclast activity caused by PTH leads to bone resorption and the release of calcium and phosphate into the blood. However, the renal loss of phosphate is greater than the increase in serum phosphate due to osteoclast activity, resulting in an overall decrease in serum phosphate levels.

Understanding Parathyroid Hormone and Its Effects

Parathyroid hormone is a hormone produced by the chief cells of the parathyroid glands. Its main function is to increase the concentration of calcium in the blood by stimulating the PTH receptors in the kidney and bone. This hormone has a short half-life of only 4 minutes.

The effects of parathyroid hormone are mainly seen in the bone, kidney, and intestine. In the bone, PTH binds to osteoblasts, which then signal to osteoclasts to resorb bone and release calcium. In the kidney, PTH promotes the active reabsorption of calcium and magnesium from the distal convoluted tubule, while decreasing the reabsorption of phosphate. In the intestine, PTH indirectly increases calcium absorption by increasing the activation of vitamin D, which in turn increases calcium absorption.

Overall, understanding the role of parathyroid hormone is important in maintaining proper calcium levels in the body. Any imbalances in PTH secretion can lead to various disorders such as hyperparathyroidism or hypoparathyroidism.

Understanding Parathyroid Hormone and Its Effects

Parathyroid hormone is a hormone produced by the chief cells of the parathyroid glands. Its main function is to increase the concentration of calcium in the blood by stimulating the PTH receptors in the kidney and bone. This hormone has a short half-life of only 4 minutes.

The effects of parathyroid hormone are mainly seen in the bone, kidney, and intestine. In the bone, PTH binds to osteoblasts, which then signal to osteoclasts to resorb bone and release calcium. In the kidney, PTH promotes the active reabsorption of calcium and magnesium from the distal convoluted tubule, while decreasing the reabsorption of phosphate. In the intestine, PTH indirectly increases calcium absorption by increasing the activation of vitamin D, which in turn increases calcium absorption.

Overall, understanding the role of parathyroid hormone is important in maintaining proper calcium levels in the body. Any imbalances in PTH secretion can lead to various disorders such as hyperparathyroidism or hypoparathyroidism.

Differentiating Hypoglycaemia from Diabetic Ketoacidosis in Critically Ill Patients

When assessing a critically ill patient, it is important not to forget the E in the ABCDE algorithm. In the case of a woman presenting acutely, with a normal respiratory rate, it is more likely that she is hypoglycaemic rather than experiencing diabetic ketoacidosis (DKA). To confirm this, it is essential to check her glucose or blood sugar levels and then administer glucose as necessary.

It is crucial to differentiate between hypoglycaemia and DKA as the treatment for each condition is vastly different. While hypoglycaemia requires immediate administration of glucose, DKA requires insulin therapy and fluid replacement. Therefore, a correct diagnosis is essential to ensure the patient receives the appropriate treatment promptly.

In conclusion, when assessing a critically ill patient, it is vital to consider all aspects of the ABCDE algorithm, including the often-overlooked E for exposure. In cases where a patient presents acutely, with a normal respiratory rate, it is essential to differentiate between hypoglycaemia and DKA by checking glucose levels and administering glucose or insulin therapy accordingly.

Insulin is a hormone produced by the pancreas that plays a crucial role in regulating the metabolism of carbohydrates and fats in the body. It works by causing cells in the liver, muscles, and fat tissue to absorb glucose from the bloodstream, which is then stored as glycogen in the liver and muscles or as triglycerides in fat cells. The human insulin protein is made up of 51 amino acids and is a dimer of an A-chain and a B-chain linked together by disulfide bonds. Pro-insulin is first formed in the rough endoplasmic reticulum of pancreatic beta cells and then cleaved to form insulin and C-peptide. Insulin is stored in secretory granules and released in response to high levels of glucose in the blood. In addition to its role in glucose metabolism, insulin also inhibits lipolysis, reduces muscle protein loss, and increases cellular uptake of potassium through stimulation of the Na+/K+ ATPase pump.

The correct answer is Glucagon, as it is the first hormone to be secreted in response to hypoglycaemia. The patient’s reduced level of consciousness is likely due to profound hypoglycaemia caused by exogenous insulin administration. Borderline personality disorder patients have a higher incidence of self harm and suicidality than the general population. Insulin is not the correct answer as its secretion decreases in response to hypoglycaemia, and this patient has T1DM resulting in an absolute deficiency. Cortisol is also not the correct answer as it takes longer to be secreted, although it is another counter-regulatory hormone that seeks to raise blood glucose levels in response to hypoglycaemia.

Understanding Hypoglycaemia: Causes, Features, and Management

Hypoglycaemia is a condition characterized by low blood sugar levels, which can lead to a range of symptoms and complications. There are several possible causes of hypoglycaemia, including insulinoma, liver failure, Addison’s disease, and alcohol consumption. The physiological response to hypoglycaemia involves hormonal and sympathoadrenal responses, which can result in autonomic and neuroglycopenic symptoms. While blood glucose levels and symptom severity are not always correlated, common symptoms of hypoglycaemia include sweating, shaking, hunger, anxiety, nausea, weakness, vision changes, confusion, and dizziness. In severe cases, hypoglycaemia can lead to convulsions or coma.

Managing hypoglycaemia depends on the severity of the symptoms and the setting in which it occurs. In the community, individuals with diabetes who inject insulin may be advised to consume oral glucose or a quick-acting carbohydrate such as GlucoGel or Dextrogel. A ‘HypoKit’ containing glucagon may also be prescribed for home use. In a hospital setting, treatment may involve administering a quick-acting carbohydrate or subcutaneous/intramuscular injection of glucagon for unconscious or unable to swallow patients. Alternatively, intravenous glucose solution may be given through a large vein.

Overall, understanding the causes, features, and management of hypoglycaemia is crucial for individuals with diabetes or other conditions that increase the risk of low blood sugar levels. Prompt and appropriate treatment can help prevent complications and improve outcomes.

Understanding Gynaecomastia: Causes and Drug Triggers

Gynaecomastia is a condition characterized by the abnormal growth of breast tissue in males, often caused by an increased ratio of oestrogen to androgen. It is important to distinguish the causes of gynaecomastia from those of galactorrhoea, which is caused by the actions of prolactin on breast tissue.

Physiological changes during puberty can lead to gynaecomastia, but it can also be caused by syndromes with androgen deficiency such as Kallmann and Klinefelter’s, testicular failure due to mumps, liver disease, testicular cancer, and hyperthyroidism. Additionally, haemodialysis and ectopic tumour secretion can also trigger gynaecomastia.

Drug-induced gynaecomastia is also a common cause, with spironolactone being the most frequent trigger. Other drugs that can cause gynaecomastia include cimetidine, digoxin, cannabis, finasteride, GnRH agonists like goserelin and buserelin, oestrogens, and anabolic steroids. However, it is important to note that very rare drug causes of gynaecomastia include tricyclics, isoniazid, calcium channel blockers, heroin, busulfan, and methyldopa.

In summary, understanding the causes and drug triggers of gynaecomastia is crucial in diagnosing and treating this condition.

Patients who take systemic corticosteroids over a long period of time are at a higher risk of developing osteoporosis and experiencing fractures. In this case, the patient’s hip fracture may have been caused by her pre-existing osteoporosis.

Corticosteroids are commonly prescribed medications that can be taken orally or intravenously, or applied topically. They mimic the effects of natural steroids in the body and can be used to replace or supplement them. However, the use of corticosteroids is limited by their numerous side effects, which are more common with prolonged and systemic use. These side effects can affect various systems in the body, including the endocrine, musculoskeletal, gastrointestinal, ophthalmic, and psychiatric systems. Some of the most common side effects include impaired glucose regulation, weight gain, osteoporosis, and increased susceptibility to infections. Patients on long-term corticosteroids should have their doses adjusted during intercurrent illness, and the medication should not be abruptly withdrawn to avoid an Addisonian crisis. Gradual withdrawal is recommended for patients who have received high doses or prolonged treatment.

Carbimazole, although generally safe, can have a rare but severe side effect of bone marrow suppression. This can lead to a weakened immune system due to low white blood cells, specifically neutrophils, resulting in neutropenia and agranulocytosis. The most common symptom of this is a sore throat, and if this occurs, treatment with carbimazole should be discontinued.

Hair loss and headaches are common side effects but are not considered harmful to the patient’s health. Other reported side effects include nausea, stomach pains, itchy skin, rashes, and muscle and joint pain.

It is important to note that chest pain and changes in vision are not known side effects of carbimazole.

Carbimazole is a medication used to treat thyrotoxicosis, a condition where the thyroid gland produces too much thyroid hormone. It is usually given in high doses for six weeks until the patient’s thyroid hormone levels become normal, after which the dosage is reduced. The drug works by blocking thyroid peroxidase, an enzyme that is responsible for coupling and iodinating the tyrosine residues on thyroglobulin, which ultimately leads to a reduction in thyroid hormone production. In contrast, propylthiouracil has a dual mechanism of action, inhibiting both thyroid peroxidase and 5′-deiodinase, which reduces the peripheral conversion of T4 to T3.

However, carbimazole is not without its adverse effects. One of the most serious side effects is agranulocytosis, a condition where the body’s white blood cell count drops significantly, making the patient more susceptible to infections. Additionally, carbimazole can cross the placenta and affect the developing fetus, although it may be used in low doses during pregnancy under close medical supervision. Overall, carbimazole is an effective medication for managing thyrotoxicosis, but its potential side effects should be carefully monitored.

Understanding Androgens and Male Hormones

Androgens are the primary male sex hormones that play a crucial role in the development and functioning of reproductive organs and secondary sex characteristics. Testosterone is the main androgen, while dihydrotestosterone and androstenedione are other types. These hormones are also essential in maintaining bone density and mass to prevent osteoporosis.

The regulation of hormone levels in the body relies on negative feedback. Luteinising hormone (LH) stimulates the Leydig cells in the testes to produce testosterone, which is synthesized from cholesterol. When testosterone levels are high, LH is suppressed through negative feedback. A small amount of testosterone is also produced in the adrenal glands.

Other important male hormones include follicle-stimulating hormone (FSH) and dihydrotestosterone (DHT). DHT and testosterone bind to the same androgen receptors, contributing to the development of external genitalia in the fetus, secondary sex characteristics during puberty, and sperm production. DHT is a form of endogenous testosterone converted by the enzyme 5 alpha-reductase in the prostate.

FSH and testosterone work together to stimulate the Sertoli cells in the testes to secrete androgen-binding protein, which binds to testosterone to maintain high levels. Androgen-binding protein is secreted into the lumen of the seminiferous tubules and interstitial fluid around spermatogenic cells. Once the required level of spermatogenesis is achieved, inhibin prevents the release of more FSH.

In summary, understanding the role of androgens and male hormones is crucial in comprehending male reproductive health and development.

Disorders of sex hormones can have various effects on the body, as shown in the table below. Primary hypogonadism, also known as Klinefelter’s syndrome, is characterized by high levels of gonadotrophins and low levels of testosterone. Patients with this condition often have small, firm testes, lack secondary sexual characteristics, and are infertile. They may also experience gynaecomastia, which increases their risk of breast cancer. Diagnosis is made through chromosomal analysis.

Hypogonadotrophic hypogonadism, or Kallmann syndrome, is a cause of delayed puberty due to low levels of sex hormones. It is usually inherited as an X-linked recessive trait and is caused by the failure of GnRH-secreting neurons to migrate to the hypothalamus. Patients with this condition may have hypogonadism, cryptorchidism, anosmia, and low sex hormone levels. However, their LH and FSH levels are inappropriately low or normal. They are typically of normal or above-average height, but may also have cleft lip/palate and visual/hearing defects.

Androgen insensitivity syndrome is an X-linked recessive condition that causes end-organ resistance to testosterone, resulting in genotypically male children (46XY) having a female phenotype. This condition is also known as complete androgen insensitivity syndrome or testicular feminisation syndrome. Patients with this condition may experience primary amenorrhoea, undescended testes causing groin swellings, and breast development due to the conversion of testosterone to oestradiol. Diagnosis is made through a buccal smear or chromosomal analysis to reveal a 46XY genotype. Management involves counselling to raise the child as female, bilateral orchidectomy to reduce the risk of testicular cancer due to undescended testes, and oestrogen therapy.

Digoxin is the correct answer as it can lead to drug-induced gynaecomastia. Sam is likely taking digoxin due to his heart failure, and this medication has a side effect of causing breast tissue growth in men. This is thought to occur because digoxin has a similar structure to oestrogen and can directly stimulate oestrogen receptors.

While cirrhosis can also cause gynaecomastia, it is unlikely in this case as there are no signs or symptoms of liver disease. Cirrhosis typically causes gynaecomastia due to the liver’s reduced ability to clear oestrogens from the bloodstream.

Obesity is not the correct answer as Sam is not obese, with a BMI of 24 kg/m². However, obesity is a common cause of gynaecomastia as excess fat can be distributed to the breasts and result in increased aromatisation of androgens to oestrogens.

An oestrogen-secreting tumour is not the correct answer as there is no evidence in Sam’s history or examination to suggest he has one, although these tumours can cause gynaecomastia in men.

Understanding Gynaecomastia: Causes and Drug Triggers

Gynaecomastia is a condition characterized by the abnormal growth of breast tissue in males, often caused by an increased ratio of oestrogen to androgen. It is important to distinguish the causes of gynaecomastia from those of galactorrhoea, which is caused by the actions of prolactin on breast tissue.

Physiological changes during puberty can lead to gynaecomastia, but it can also be caused by syndromes with androgen deficiency such as Kallmann and Klinefelter’s, testicular failure due to mumps, liver disease, testicular cancer, and hyperthyroidism. Additionally, haemodialysis and ectopic tumour secretion can also trigger gynaecomastia.

Drug-induced gynaecomastia is also a common cause, with spironolactone being the most frequent trigger. Other drugs that can cause gynaecomastia include cimetidine, digoxin, cannabis, finasteride, GnRH agonists like goserelin and buserelin, oestrogens, and anabolic steroids. However, it is important to note that very rare drug causes of gynaecomastia include tricyclics, isoniazid, calcium channel blockers, heroin, busulfan, and methyldopa.

In summary, understanding the causes and drug triggers of gynaecomastia is crucial in diagnosing and treating this condition.

Acromegaly is a condition that results from excessive growth hormone production. The release of growth hormone is directly inhibited by somatostatin, which is why somatostatin analogues are used to treat acromegaly.

To answer the question, one must first recognize the symptoms of acromegaly, such as carpal tunnel syndrome, sleep apnea, and changes in facial features over time. The second part of the question involves identifying octreotide as a somatostatin analogue commonly used to treat acromegaly.

While dopamine agonists were previously used to treat acromegaly, they are no longer preferred due to the availability of more effective treatments. Dopamine antagonists have never been used to treat acromegaly. Pegvisomant is an example of a growth hormone antagonist, but antagonists for insulin growth factor-1 release have not yet been developed.

Acromegaly is a condition that can be managed through various treatment options. The first-line treatment for the majority of patients is trans-sphenoidal surgery. However, if the pituitary tumour is inoperable or surgery is unsuccessful, medication may be indicated. One such medication is a somatostatin analogue, which directly inhibits the release of growth hormone. Octreotide is an example of this medication and is effective in 50-70% of patients. Another medication is pegvisomant, which is a GH receptor antagonist that prevents dimerization of the GH receptor. It is administered once daily subcutaneously and is very effective, decreasing IGF-1 levels in 90% of patients to normal. However, it does not reduce tumour volume, so surgery is still needed if there is a mass effect. Dopamine agonists, such as bromocriptine, were the first effective medical treatment for acromegaly but are now superseded by somatostatin analogues and are only effective in a minority of patients. External irradiation may be used for older patients or following failed surgical/medical treatment.

Aldosterone is produced in the zona glomerulosa of the adrenal gland.

Renin is released by juxtaglomerular cells located in the nephron.

ACE is produced by the pulmonary endothelium in the lungs.

The adrenal gland is composed of the zona glomerulosa, fasciculata, and reticularis.

Glucocorticoids are produced in the zona fasciculata.

Adrenal Physiology: Medulla and Cortex

The adrenal gland is composed of two main parts: the medulla and the cortex. The medulla is responsible for secreting the catecholamines noradrenaline and adrenaline, which are released in response to sympathetic nervous system stimulation. The chromaffin cells of the medulla are innervated by the splanchnic nerves, and the release of these hormones is triggered by the secretion of acetylcholine from preganglionic sympathetic fibers. Phaeochromocytomas, which are tumors derived from chromaffin cells, can cause excessive secretion of both adrenaline and noradrenaline.

The adrenal cortex is divided into three distinct zones: the zona glomerulosa, zona fasciculata, and zona reticularis. Each zone is responsible for secreting different hormones. The outer zone, zona glomerulosa, secretes aldosterone, which regulates electrolyte balance and blood pressure. The middle zone, zona fasciculata, secretes glucocorticoids, which are involved in the regulation of metabolism, immune function, and stress response. The inner zone, zona reticularis, secretes androgens, which are involved in the development and maintenance of male sex characteristics.

Most of the hormones secreted by the adrenal cortex, including glucocorticoids and aldosterone, are bound to plasma proteins in the circulation. Glucocorticoids are inactivated and excreted by the liver. Understanding the physiology of the adrenal gland is important for the diagnosis and treatment of various endocrine disorders.

Throughout adulthood, the maintenance of tissues still relies on sufficient levels of growth hormone. This hormone not only promotes growth, but also supports cellular regeneration and reproduction. While it is crucial for normal growth during childhood, it also helps to preserve muscle mass, facilitate organ growth, and boost the immune system, making its lifelong release necessary. Therefore, growth hormone is a key factor in growth during all stages of life, including before, during, and after puberty.

Understanding Growth Hormone and Its Functions

Growth hormone (GH) is a hormone produced by the somatotroph cells in the anterior pituitary gland. It plays a crucial role in postnatal growth and development, as well as in regulating protein, lipid, and carbohydrate metabolism. GH acts on a transmembrane receptor for growth factor, leading to receptor dimerization and direct or indirect effects on tissues via insulin-like growth factor 1 (IGF-1), which is primarily secreted by the liver.

GH secretion is regulated by various factors, including growth hormone releasing hormone (GHRH), fasting, exercise, and sleep. Conversely, glucose and somatostatin can decrease GH secretion. Disorders associated with GH include acromegaly, which results from excess GH, and GH deficiency, which can lead to short stature.

In summary, GH is a vital hormone that plays a significant role in growth and metabolism. Understanding its functions and regulation can help in the diagnosis and treatment of GH-related disorders.

Understanding Multiple Endocrine Neoplasia

Multiple endocrine neoplasia (MEN) is an autosomal dominant disorder that affects the endocrine system. There are three main types of MEN, each with its own set of associated features. MEN type I is characterized by the 3 P’s: parathyroid hyperplasia leading to hyperparathyroidism, pituitary tumors, and pancreatic tumors such as insulinomas and gastrinomas. MEN type IIa is associated with the 2 P’s: parathyroid hyperplasia leading to hyperparathyroidism and phaeochromocytoma, as well as medullary thyroid cancer. MEN type IIb is characterized by phaeochromocytoma, medullary thyroid cancer, and a marfanoid body habitus.

The most common presentation of MEN is hypercalcaemia, which is often seen in MEN type I due to parathyroid hyperplasia. MEN type IIa and IIb are both associated with medullary thyroid cancer, which is caused by mutations in the RET oncogene. MEN type I is caused by mutations in the MEN1 gene. Understanding the different types of MEN and their associated features is important for early diagnosis and management of this rare but potentially serious condition.

The insertion of aquaporin-2 channels by antidiuretic hormone promotes water reabsorption, which is compromised in central diabetes insipidus (DI) caused by physical trauma to the pituitary gland. Symptoms include increased thirst, polydipsia, and polyuria, with urinalysis showing decreased urine osmolality and sodium concentration. Aldosterone regulates epithelial sodium channel (ENaC) and K+/H+ exchanger, while angiotensin II regulates Na+/H+ exchanger in proximal tubules. Loop diuretics decrease activity of Na-K-Cl cotransporter in the loops of Henle. However, none of these are relevant to this patient’s presentation.

Understanding Antidiuretic Hormone (ADH)

Antidiuretic hormone (ADH) is a hormone that is produced in the supraoptic nuclei of the hypothalamus and released by the posterior pituitary gland. Its primary function is to conserve body water by promoting water reabsorption in the collecting ducts of the kidneys through the insertion of aquaporin-2 channels.

ADH secretion is regulated by various factors. An increase in extracellular fluid osmolality, a decrease in volume or pressure, and the presence of angiotensin II can all increase ADH secretion. Conversely, a decrease in extracellular fluid osmolality, an increase in volume, a decrease in temperature, or the absence of ADH can decrease its secretion.

Diabetes insipidus (DI) is a condition that occurs when there is either a deficiency of ADH (cranial DI) or an insensitivity to ADH (nephrogenic DI). Cranial DI can be treated with desmopressin, which is an analog of ADH.

Overall, understanding the role of ADH in regulating water balance in the body is crucial for maintaining proper hydration and preventing conditions like DI.

The water deprivation test is a diagnostic tool used to assess patients with polydipsia, or excessive thirst. During the test, the patient is instructed to refrain from drinking water, and their bladder is emptied. Hourly measurements of urine and plasma osmolalities are taken to monitor changes in the body’s fluid balance. The results of the test can help identify the underlying cause of the patient’s polydipsia. Normal results show a high urine osmolality after the administration of DDAVP, while psychogenic polydipsia is characterized by a low urine osmolality. Cranial DI and nephrogenic DI are both associated with high plasma osmolalities and low urine osmolalities.

Understanding Growth and Factors Affecting It

Growth is a significant difference between children and adults, and it occurs in three stages: infancy, childhood, and puberty. Several factors affect fetal growth, including environmental, placental, hormonal, and genetic factors. Maternal nutrition and uterine capacity are the most crucial environmental factors that affect fetal growth.

In infancy, nutrition and insulin are the primary drivers of growth. High fetal insulin levels result from poorly controlled diabetes in the mother, leading to hypoglycemia and macrosomia in the baby. Growth hormone is not a significant factor in infancy, as babies have low amounts of receptors. Hypopituitarism and thyroid have no effect on growth in infancy.

In childhood, growth is driven by growth hormone and thyroxine, while in puberty, growth is driven by growth hormone and sex steroids. Genetic factors are the most important determinant of final adult height.

It is essential to monitor growth in children regularly. Infants aged 0-1 years should have at least five weight recordings, while children aged 1-2 years should have at least three weight recordings. Children older than two years should have annual weight recordings. Children below the 2nd centile for height should be reviewed by their GP, while those below the 0.4th centile for height should be reviewed by a paediatrician.

In Addison’s disease, there is a deficiency in the production of both aldosterone and cortisol.

Aldosterone plays a crucial role in the reabsorption of sodium and the excretion of potassium.

Therefore, the absence of aldosterone leads to an imbalance in the levels of sodium and potassium in the body, resulting in hyperkalemia (high potassium levels) and hyponatremia (low sodium levels).

Addison’s disease is the most common cause of primary hypoadrenalism in the UK, with autoimmune destruction of the adrenal glands being the main culprit, accounting for 80% of cases. This results in reduced production of cortisol and aldosterone. Symptoms of Addison’s disease include lethargy, weakness, anorexia, nausea and vomiting, weight loss, and salt-craving. Hyperpigmentation, especially in palmar creases, vitiligo, loss of pubic hair in women, hypotension, hypoglycemia, and hyponatremia and hyperkalemia may also be observed. In severe cases, a crisis may occur, leading to collapse, shock, and pyrexia.

Other primary causes of hypoadrenalism include tuberculosis, metastases (such as bronchial carcinoma), meningococcal septicaemia (Waterhouse-Friderichsen syndrome), HIV, and antiphospholipid syndrome. Secondary causes include pituitary disorders, such as tumours, irradiation, and infiltration. Exogenous glucocorticoid therapy can also lead to hypoadrenalism.

It is important to note that primary Addison’s disease is associated with hyperpigmentation, while secondary adrenal insufficiency is not.

Low cortisol production and compensatory adrenal hyperplasia are caused by 21-hydroxylase deficiency, leading to increased androgen production and ambiguous genitalia. The enzymes 11-beta hydroxylase and 17-hydroxylase are also involved. Testosterone and estrogen synthesis is not affected as they are produced in the testes and ovaries, respectively. Congenital adrenal hyperplasia is not caused by aldosterone synthesis, despite it occurring in the adrenal cortex.

Congenital adrenal hyperplasia is a genetic condition that affects the adrenal glands and can result in various symptoms depending on the specific enzyme deficiency. One common form is 21-hydroxylase deficiency, which can cause virilization of female genitalia, precocious puberty in males, and a salt-losing crisis in 60-70% of patients during the first few weeks of life. Another form is 11-beta hydroxylase deficiency, which can also cause virilization and precocious puberty, as well as hypertension and hypokalemia. A third form is 17-hydroxylase deficiency, which typically does not cause virilization in females but can result in intersex characteristics in boys and hypertension.

Overall, congenital adrenal hyperplasia can have significant impacts on a person’s physical development and health, and early diagnosis and treatment are important for managing symptoms and preventing complications.

The sensitivity of the body to catecholamines is heightened by thyroid hormones. When catecholamines activate the β1 receptors in the heart, it leads to an elevation in heart rate.

Thyroid disorders are commonly encountered in clinical practice, with hypothyroidism and thyrotoxicosis being the most prevalent. Women are ten times more likely to develop these conditions than men. The thyroid gland is a bi-lobed structure located in the anterior neck and is part of a hypothalamus-pituitary-end organ system that regulates the production of thyroxine and triiodothyronine hormones. These hormones help regulate energy sources, protein synthesis, and the body’s sensitivity to other hormones. Hypothyroidism can be primary or secondary, while thyrotoxicosis is mostly primary. Autoimmunity is the leading cause of thyroid problems in the developed world.

Thyroid disorders can present in various ways, with symptoms often being the opposite depending on whether the thyroid gland is under or overactive. For example, hypothyroidism may result in weight gain, while thyrotoxicosis leads to weight loss. Thyroid function tests are the primary investigation for diagnosing thyroid disorders. These tests primarily look at serum TSH and T4 levels, with T3 being measured in specific cases. TSH levels are more sensitive than T4 levels for monitoring patients with existing thyroid problems.

Treatment for thyroid disorders depends on the cause. Patients with hypothyroidism are given levothyroxine to replace the underlying deficiency. Patients with thyrotoxicosis may be treated with propranolol to control symptoms such as tremors, carbimazole to reduce thyroid hormone production, or radioiodine treatment.

Extra-adrenal tumors are often located near the aortic bifurcation and can be identified through a urinary free adrenaline test, which measures the levels of adrenaline and noradrenaline produced by the adrenal medulla. Meanwhile, a 24-hour urinary free cortisol test is used to diagnose Cushing’s Disease, which is caused by excessive cortisol production from the zona fasciculata of the adrenal cortex. The aldosterone-renin ratio test is used to diagnose Conn’s Disease, which is caused by excessive aldosterone production from the zona glomerulosa of the adrenal cortex. Androgens are produced by the zona reticularis of the adrenal cortex. Addison’s Disease, a deficiency of cortisol, can be diagnosed through a short synacthen test.

Adrenal Physiology: Medulla and Cortex

The adrenal gland is composed of two main parts: the medulla and the cortex. The medulla is responsible for secreting the catecholamines noradrenaline and adrenaline, which are released in response to sympathetic nervous system stimulation. The chromaffin cells of the medulla are innervated by the splanchnic nerves, and the release of these hormones is triggered by the secretion of acetylcholine from preganglionic sympathetic fibers. Phaeochromocytomas, which are tumors derived from chromaffin cells, can cause excessive secretion of both adrenaline and noradrenaline.

The adrenal cortex is divided into three distinct zones: the zona glomerulosa, zona fasciculata, and zona reticularis. Each zone is responsible for secreting different hormones. The outer zone, zona glomerulosa, secretes aldosterone, which regulates electrolyte balance and blood pressure. The middle zone, zona fasciculata, secretes glucocorticoids, which are involved in the regulation of metabolism, immune function, and stress response. The inner zone, zona reticularis, secretes androgens, which are involved in the development and maintenance of male sex characteristics.

Most of the hormones secreted by the adrenal cortex, including glucocorticoids and aldosterone, are bound to plasma proteins in the circulation. Glucocorticoids are inactivated and excreted by the liver. Understanding the physiology of the adrenal gland is important for the diagnosis and treatment of various endocrine disorders.

The two main factors that contribute to diabetic foot disease are loss of sensation and peripheral arterial disease. When reviewing a diabetic patient who presents with a complication, it is crucial to recognize that those with a loss of protective sensation are at a high risk of developing diabetic foot disease. Therefore, any ulcers must be promptly managed to prevent severe infection.

Out of the given options, the most appropriate next step in managing this patient is to conduct a full neurovascular examination of their lower limbs. While checking the HbA1C levels is important, it is not the immediate concern for this patient. Similarly, examining foot sensation using a 10g monofilament is a crucial step, but it is only a part of a comprehensive neurovascular examination. Measuring C-peptide is not relevant to the current situation.

Diabetic foot disease is a significant complication of diabetes mellitus that requires regular screening. In 2015, NICE published guidelines on diabetic foot disease. The disease is caused by two main factors: neuropathy, which results in a loss of protective sensation, and peripheral arterial disease, which can cause macro and microvascular ischaemia. Symptoms of diabetic foot disease include loss of sensation, absent foot pulses, reduced ankle-brachial pressure index (ABPI), intermittent claudication, calluses, ulceration, Charcot’s arthropathy, cellulitis, osteomyelitis, and gangrene.

All patients with diabetes should be screened for diabetic foot disease at least once a year. Screening for ischaemia involves palpating for both the dorsalis pedis pulse and posterial tibial artery pulse, while screening for neuropathy involves using a 10 g monofilament on various parts of the sole of the foot. NICE recommends that patients be risk-stratified into low, moderate, and high-risk categories based on factors such as deformity, previous ulceration or amputation, renal replacement therapy, and the presence of calluses or neuropathy. Patients who are moderate or high-risk should be regularly followed up by their local diabetic foot centre.